CRO concept stocks collectively rebounded. As of press time, Tigermed (03347) rose 9.19% to HK$39.92; WuXi AppTec (02359) gained 4.43% to HK$106; Pharmaron (03759) climbed 4.15% to HK$21.58; WuXi Biologics (02269) increased 3.27% to HK$31.56.

CMB International believes that the recovery in capital market financing activities, expansion of overseas innovative drug transactions, rebounding domestic R&D demand, and the U.S. interest rate cut cycle could drive a performance recovery for CXO companies in the second half of the year. The firm expects clinical developments of licensed innovative drug pipelines overseas to become a key catalyst for the sector.

Morgan Stanley noted in a report that healthcare stocks have faced sustained selling since mid-September as investors lock in profits and await signals for next year's performance. The bank highlighted that WuXi group stocks, backed by solid fundamentals, now offer more attractive valuations. Morgan Stanley is most bullish on WuXi AppTec, citing its raised earnings guidance, large-scale capacity expansion, and strong involvement in next-generation GLP-1 therapies.

Overall, WuXi AppTec, WuXi Biologics, and WuXi XDC are projected to achieve 2024-27 earnings CAGRs of 24%, 23%, and 37%, respectively.